A recent study suggested that the cadherin gene FAT exerts an influence on susceptibility to bipolar affective disorder (BPAD). We aimed to replicate this finding in a German sample (425 BPAD I and 419 controls). In addition, we performed a comprehensive linkage disequilibrium mapping of the whole genomic region of FAT and the neighboring circadian gene MTNR1A (48 single nucleotide polymorphisms (SNPs) covering 191 kb). No significant association was observed for SNPs located in the MTNR1A gene. In FAT, however, nine SNPs showed association, eight of them being located in the same haplotype block found to be associated with BPAD by Blair et al. The smallest P-value of 0.00028 (OR 1.71) was seen for nonsynonymous SNP rs2637777. A combination of five markers including this marker showed a haplotype distribution with a nominal P-value of 1.8 Â 10
Introduction
Bipolar affective disorder (BPAD (MIM 125480)) is a major psychiatric illness characterized by aberrant mood swings. It has a lifetime prevalence of 0.5-1.5% in all populations worldwide and constitutes a major public health problem, with significant morbidity and mortality (World Health Organization). 1 Family, twin and adoption studies strongly implicate a hereditary component to BPAD. 2 In recent years, an accumulation of evidence from linkage studies combined with both progress in the human genome project and the development of high-throughput genotyping technology has rendered the process of searching for the involved genes more efficient. As a result, several genes have recently been identified as promising BPAD susceptibility genes, including DAOA (G72/ G30), DISC1, BDNF and GRIN1. Most of these genes were initially identified in schizophrenia samples through use of a positional cloning strategy, where a genome-wide linkage step was used as a starting point and subsequent fine mapping/linkage disequilibrium (LD) steps then guided researchers to the relevant susceptibility gene. In subsequent studies, these genes were also found to be associated with BPAD. Blair et al. (2006) 3 recently reported the identification of FAT as a susceptibility gene for BPAD, having applied such a strategy. The group had previously identified a susceptibility locus for BPAD on chromosome 4q35. 4 Genetic refinement and physical mapping studies enabled a narrowing down of the linkage region to 2.3 Mb. 5 Independent support for linkage of BPAD to the long arm of chromosome 4 was reported by other groups as well. [6] [7] [8] Blair et al. (2006) performed systematic LD studies in the candidate region and found evidence suggesting that a haplotype block at the 3 0 end of the cadherin gene FAT (the homolog of the Drosophila tumor suppressor gene FAT) confers susceptibility to BPAD. Haplotype TACTG of the five single nucleotide polymorphisms (SNP)-combination, rs2306987, rs1298865, rs2306990, rs2637777 and rs2304865, was associated in an Australian patient-control sample of 71 family history positive patients and 66 controls (65 of the patients being index cases from BPAD families that had been recruited for linkage analyses). Three of these SNPs, rs2306987, rs1298865 and rs2304865, were subsequently genotyped in 669 patients and 679 controls from the United Kingdom, but failed to show association in the overall sample. Association was observed, however, with rs1298865 and rs2304865 in a subsample of patients with a family history of psychiatric illness (59% of the total patients). In a further replication attempt, rs2306987 was analyzed in two parent-offspring trio samples from the United Kingdom and Bulgaria. Association was found for the subgroup of trios whose index patients had experienced a psychotic episode.
The associated SNPs found in these studies are localized within a part of the FAT gene that encodes an intracellular domain (EVH1), which interacts with both Ena/VASP proteins and putative b-catenin binding sites. Expression analyses in mice administered with lithium and valproate showed FAT to be significantly downregulated. Blair and colleagues conclude that these data provide convergent evidence that FAT and its protein partners may be components of a molecular pathway involved in susceptibility to bipolar disorder.
Given the importance of independent replication of association findings in genetically complex diseases, we investigated these findings in an independent patient-control sample of German descent. We also performed a systematic LD study of the genomic region comprising the FAT gene and the circadian gene MTNR1A which is located in close proximity to FAT and which has also been proposed as a possible candidate gene for BPAD. 9 
Materials and methods
To determine the relevance of FAT and MTNR1A to the development of BPAD in the German population, we selected and tested 48 SNP markers (Table 1) , distributed over 191 401 bp (from 187 691 803 bp through to 187 881 981 bp). According to the haplotype structure provided by HapMap, these SNPs capture all haplotypes present at a frequency of at least 2% in the Central European (CEU) population. In regions not included in haplotype blocks, we tested all SNPs at a minor allele frequency of 10%. We genotyped all 48 SNPs in a sample of 425 BPAD patients (52.7% female and 47.3% male, mean age of 43.6710.9) and 419 controls (44.6% female and 55.4% male, mean age 48.4715.6 years). Diagnostic assessments using a best estimate approach were performed using a comprehensive inventory for phenotype characterization-IPGS. 10 This included a SCID-I Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth edition and the OPCRIT system as well as a review of medical records. 11, 12 All interviews were conducted by trained raters. Consensus diagnoses were performed by two psychiatrists, additional psychiatrists being included in the decision making process when necessary. All individuals participating in the study were of German descent. The genotyping was performed using Illumina's Golden Gate Assays. Genotype call rate was > 98% for all markers, and there were no replicate errors among 2% of the samples genotyped in duplicate. Departure from Hardy-Weinberg equilibrium was tested using a w 2 -test (1 d.f.). Single-marker association analysis was performed using the Cochrane-Armitage trend test. 13 Power calculations were conducted using the Genetic Power Calculator. 14 Haplotype distributions in patients and controls were compared using FAMHAP. 15 All marker combinations were tested by comparing haplotype frequency distribution between patients and controls for all possible marker combinations. 16 For each marker combination, a global P-value, corrected for multiple testing, was computed using Monte-Carlo simulations. 16 Assuming an additive model, our patient/ control sample had a power of > 97% at a = 0.05 to detect the genetic effect found for rs2306987, rs1298865 and rs2304865 by Blair et al. Given that Blair et al. found stronger association when stratifying for psychotic symptoms and familial aggregation (positive family history), we undertook similar analyses. In addition, we stratified for further phenotypic symptoms that may be representative of greater etiological homogeneity. We subdivided the sample according to the presence of a positive family history of psychiatric illness in first and second degree relatives (FH, n = 290), a lifetime history of psychotic symptoms (Psych, n = 272), a lifetime history of persecutory delusions (PerDel, n = 157), and an early age of onset ( < 21 years, n = 126).
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Results
Results obtained for the FAT locus
Of the 33 SNPs tested at the FAT locus, 9 (rs4862718, rs7683023, rs2306987, rs1298865, rs2306990, rs10009030, rs2637777, rs2304865 and rs328437) showed association with BPAD. The strongest evidence was obtained for rs1298865 and rs2637777 (P-value = 0.00079 and P-value = 0.00028, respectively, Table 1 ) and remained significant after Monte-Carlo simulation-based multiple comparison adjustment (corrected P-value for rs2637777 is 0.008, using FAMHAP options 'maxmarker 1 hapcc u subu1' for case-control data). All five SNPs reported to be associated with BPAD by Blair et al. (rs2306987, rs1298865, rs2306990, rs2637777 and rs2304865) were also significantly associated in our sample. Allele frequencies of rs2306987, rs2304865 and rs1298865 between Australian, UK and German control samples did not differ significantly. The same was true for allele frequencies between the UK and German patients. However, allele frequencies differed significantly between our German patient sample and both the stratified UK and Australian patient samples (Supplementary Table 2 ). These significant 
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FAT and BPADdifferences are the result of opposite tendencies of the associated alleles. For example, whereas the allele G of the rs1298865 has very comparable frequencies across all control samples (10-11%), it has a frequency of 17% in the German patients, but a frequency of only 9% in the Australian and stratified UK cases. Assuming this is not a false positive result; this particular allele therefore represents a risk-allele in the German sample, while acting as a protective allele in the Australian and stratified UK patients. Eight of the BPAD-associated SNPs are located next to each other and define a distinct haplotype block which we termed 'D' (Table 1 and Figure 1 ). Within this block, marker combination rs2306987, rs1298865, rs10009030, rs2637777 and rs2304865 shows a global P-value of 0.000018 (0.00028 after correction for multiple testing of all marker combinations of the block according to Becker et al.
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). The frequencies of three individual haplotypes are significantly different between patients and controls: haplotype AGAGC is overrepresented in patients (35 vs 30% in controls, P-value = 0.029, OR = 1.62). The opposite haplotype, TACTG, is significantly underrepresented in the patients (59 vs 66% in controls, P-value of 0.001, OR of 0.72). The less frequent haplotype TGCGG is significantly overrepresented in patients (3 vs 1% in controls) and shows a P-value of 0.003 and an OR of 2.04. Testing the marker combination with which Blair and colleagues found their best haplotype association (rs2306987, rs1298865, rs2306990, rs2637777 and rs2304865), we also observed significant results (Pvalue for the global haplotype distribution at these markers is 0.0001) ( Figure 1 and Table 2 ). As in the single-marker analysis, the deviation from control haplotype frequencies is in the opposite direction in the German sample compared to the Australian/ stratified UK samples. The haplotype that is underrepresented in our cases, TACTG (corresponding to GTGTA in Blair et al.) is overrepresented in the Australian/stratified UK sample.
We confirmed consistency of allele designations between our study and the Blair et al. study by comparing control allele frequencies.
Results obtained for the MTNR1A locus
In the single-marker analysis, none of the 15 MTNR1A SNPs showed significant evidence of association with BPAD. Haplotype analysis, however, produced one significant result in haplotype block B. Marker combination rs11721818, rs4862709 and rs6553013 showed a corrected global P-value of 0.0331. This Pvalue is mainly due to the overrepresentation of the rare haplotype TAC (2% in patients and 0% in controls). On the basis of our data alone, it is thus difficult to judge whether this represents a 'true' or a chance finding. Replication studies in independent samples are required to clarify this. (Figure 1 ). These data suggest that all three populations investigated to date (Australian, CEPH and German) have comparable, though not identical, LD structures in this particular genomic region. 
Discussion
In the present study, we attempted to replicate the reported association between BPAD and genetic variation at the FAT locus. We tested the five markers (rs2306987, rs1298865, rs2306990, rs2637777 and rs2304865) that had shown strongest association in the Blair et al. study in a BPAD patient-control sample German descent (425 patients, 419 controls). We also tested further 43 SNPs in order to investigate the possible involvement of other SNPs/haplotype blocks in the FAT gene and the neighboring candidate gene MTNR1A.
The five markers that were associated with BPAD in the Australian sample also show evidence for association in our German sample (P-values between 0.0342 and 0.0004, Table 1 ). Stratifying for a family history of psychiatric illness and for lifetime psychotic episodes did not improve the P-values as was the case in the Blair et al. study (Supplementary Table 1 ). However, stratifying for these phenotypic items did not produce association uniformly in the Australian and UK/ Bulgarian samples either. Whereas the Australian and UK samples showed an effect for positive family history, the Bulgarian trio sample did not, but showed association in a subgroup of patients with a lifetime psychotic episode. Further independent studies are needed to determine the effect of FAT in these particular phenotypic subgroups before final conclusions can be drawn.
Beyond replicating the phenotypic stratifications applied by Blair et al., we also subgrouped our sample on an exploratory basis with regard to phenotypic items that may define more homogeneous BPAD subgroups: early age-of-onset (AOO; that is, < 21 years), and persecutory delusions (which have been described as being associated with variation in G72).
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The early AOO and persecutory delusion subgroups showed slightly stronger association (Supplementary Table 1 ). These findings, however, must be regarded as preliminary and require confirmation in independent samples.
Haplotype analysis showed evidence of association in the same region circumscribed by single-marker analysis. These results suggest that the causing variant The major difference between our findings and those of Blair et al.'s is in the direction of the associated alleles' frequencies. The successful replication of a reported disease marker but with a reversal of the risk allele has been a feature of an increasing number of publications. 21, 22 Such 'flip-flop phenomena' are difficult to interpret, particularly when they are observed in comparably recruited samples from a common population. Differences in LD architecture across populations with different ancestral origins may be one plausible theoretical explanation. In populations with a similar ancestral background, such as the Australian sample described by Blair et al. (mainly UK and Irish origin), and the UK, Bulgarian and German populations, such differences seem less likely. However, LD patterns may vary even within (sub)populations (as has been observed by 
a The marker combination which showed the most significant P-value in our study. b The marker combination which showed the most significant P-value in the study of Blair et al. 23 either as a consequence of differences in local recombination rates, genetic drift and population history, or as a result of sampling variation. When comparing the structure of the associated haplotype blocks between the Australian and German samples (Figure 1 ), slight differences are visible (the region covered by haplotype block 'D' associated in the German sample is split into two haplotype blocks in the Australian sample). Assuming that none of the BPAD-associated SNPs in our study or the Blair et al. study are causal, such slight differences in LD patterns between the studied populations could account for the observed allelic/ haplotypic inconsistencies. Interestingly, using theoretical modeling, Lin et al. also demonstrated that flipflop associations are possible within samples recruited from the same population when the investigated variants are correlated, either through interactive effects or LD, with a second causal variant. 24 They showed that such flip-flop associations are seen particularly when the risk allele at the genotyped locus is a relatively common allele (a prerequisite that is given for the associated FAT SNPs in our study; minor allele frequencies are X0.28) which is in weak LD with a yet unknown second causal variant. Under such circumstances, the observed direction of allelic association may be especially susceptible to sampling variation, and remarkable variation in LD patterns between the investigated samples is not required. 24 All of these explanations assume that the diseaseassociated variant is identical-by-descent in all BPAD samples that have shown association with FAT variants to date (Australian, UK, Bulgarian and German). An alternative explanation could be an independent mutational event occurring in the 'Australian' and 'German' BPAD-associated haplotypes.
Lastly, as long as there is no clear evidence for the presence of a variant of pathophysiological relevance in the genomic region covered by the associated haplotypes, the possibility that the association is spurious cannot be excluded.
In conclusion, our single-marker and haplotype association results support the relevance of FAT as a susceptibility factor in the etiology of BPAD. Further studies are required, however, to characterize the associated haplotype(s) more closely and to determine the causes underlying the observed flip-flop association. A detailed study of all genetic variation occurring in the genomic region covered by the associated haplotypes is necessary to enable a narrowing down of the region containing the causative variant(s). The limited extent (ca. 24.5 kb) of the BPAD-associated haplotype block ('D'; SNPs rs4862718-rs2304865; 187 737 882-187 762 357 bp) will facilitate resequencing efforts.
